A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151 on ClinicalTrials.gov · last registry update 2025-11-25
Finished 1 October 2025, after enrolling 146 people. Primary outcome, as filed: Change from Baseline in Glomerular Filtration Rate (mGFR). retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 146
- Started
- 2023-07-20
- Primary completion
- 2025-10-01 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Glomerular Filtration Rate (mGFR)
Conditions studied
Overweight or Obesity · CKD · Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.